Massive markup on high-cost drugs: Raids to continue, Karnataka writes to Centre
The next phase of raids will focus on antiretroviral drugs, higher-generation and critical antibiotics, medical devices, and hospital consumables with significant financial implications for patients
Recent inspections by the Karnataka Food Safety and Drug Administration (FSDA) have uncovered significant discrepancies in the pricing of high-cost drugs, cancer medications, antibiotics and hospital consumables. The Karnataka government has expressed concern over the disparity between the institutional landing prices paid by hospitals for these essential medicines and the Maximum Retail Prices (MRP) charged to patients.
The Union Ministry of Health and Family Welfare, the National Pharmaceutical Pricing Authority (NPPA) and Karnataka's Health and Family Welfare Minister U.T. Khader have been approached to address this issue. Investigations have revealed markups ranging from 10 times to over 52 times the actual procurement cost. The FSDA has found extreme pricing anomalies in 253 drugs, with the cancer drug Cytax 100 mg showing a markup of 11.2 times and the antibiotic Gufipol reaching 52.6 times, or 5,165%.
The Karnataka government has called for increased transparency, expanded price control measures, and an inter-ministerial expert group to tackle these issues.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.